AstraZeneca agreed to invest $2 billion in Summit Therapeutics on Monday, sending the biotech’s shares up as much as 19 percent in after-hours trading and handing the company a war chest to advance its cancer pipeline.
The premium and the stake
AstraZeneca will buy newly issued convertible preferred shares at $18.36 per common-share equivalent, an 19 percent premium to Summit’s $15.48 close. Once converted, the position translates to roughly 12 percent of outstanding stock or 10.6 percent fully diluted. The deal is expected to close within a week.
Ivonescimab and the Akeso link
The investment centers on ivonescimab, a PD-1/VEGF bispecific antibody developed by China’s Akeso. Summit holds development and commercialization rights outside China and is awaiting an FDA decision by November 14 on the drug combined with chemotherapy for EGFR-mutated non-small-cell lung cancer.
Combination trials and cash runway
Summit and AstraZeneca also plan to test ivonescimab alongside sonesitatug vedotin, AstraZeneca’s Claudin 18.2-targeting antibody-drug conjugate, starting in gastrointestinal cancers. The companies will share trial costs while keeping commercial rights to their own assets. The $2 billion infusion extends Summit’s runway for late-stage development.